
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is poised for success with its innovative ABC platform and investigational medicines; including tarcocimab, the reformulated Zenkuda (tarcocimab tedromer) and KSI-501 (anti-VEGF, anti-IL-6), and KSI-101 (anti-VEGF/anti-IL-6 without biopolymer conjugate), all expected to have significant positive impact on the retinal therapeutics pipeline following the results of the Phase 3 DAYBREAK trial and future Phase 3 PEAK and PINNACLE trials for extended efficacy and durability beyond current standard treatments. Additionally, the company's financials and portfolio diversification, along with the potential for rapid adoption as a second-line or, in some cases, first-line treatment for different indications, make it an attractive investment with a Buy rating and target price of $58 per share based on a 25x multiple of taxed and diluted 2036 EPS of $8.93 discounted back to December 2026 at 13%, and an NPV discounted cash flow between 2026-2036 of $50.50 per share, with a discount rate of 13% and growth rate of 1%. However, risks such as platform limitations and competition from other bi
Bears say
Kodiak Sciences is a pre-commercial biotechnology company that is focused on developing transformative therapeutics for retinal diseases. However, the Negative Outlook stems from concerns about competition from other biotechnology companies that are also working on treatments for retinal diseases, as well as the potential for delays or setbacks in the approval process for Kodiak's investigational medicines. Additionally, the company's financials show a net loss for the quarter and a potential need for additional capital, which could lead to share dilution.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares